Extra heart recruits for Mesoblast
Friday, 27 February, 2009
A good safety report has allowed recruitment to proceed of a further group of patients for a Phase II trial of Angioblast’s Revascor universal adult stem cell product.
Angioblast, the US-based sister company of Melbourne’s Mesoblast, is conducting a Phase II trial of Revascor in patients with congestive heart failure.
No adverse effects were recorded in the first 20 patients on a low dose of the product. Recruitment will now begin for another 20-person group to receive a higher dose.
The allogeneic stem cell product is being developed to reverse congestive heart failure by rebuilding blood vessels and heart muscle.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
